The HINT2 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from Jurkat T lymphoblasts (Homo sapiens), designed to disrupt the HINT2 gene. This loss-of-function model allows investigation of HINT2??s role in mitochondrial apoptosis, tumor suppression, and calcium signaling. The polyclonal format provides a broad genetic background of targeted disruptions suitable for population-level analyses.
Jurkat is an immortalized human T lymphocyte line established from the peripheral blood of a 14-year-old male with acute T cell leukemia. Widely used to study T cell signaling and acute lymphoblastic leukemia (ALL), Jurkat cells retain leukemic features including dysregulated survival pathways. Their intact intrinsic apoptosis machinery makes them an ideal host for probing mitochondrial cell death regulation in a T?cell leukemic context.
HINT2 is a mitochondrial protein functioning as a potent tumor suppressor, primarily through promoting intrinsic apoptosis. It facilitates the release of cytochrome c from the mitochondrial intermembrane space, enabling apoptosome assembly with Apaf-1 and subsequent activation of caspase-9, which then cleaves executioner caspase-3. Concurrently, HINT2 regulates mitochondrial protein acetylation by interacting with the deacetylase SIRT3 and the acetyltransferase GCN5L1, influencing metabolic and stress-responsive pathways. Through a direct interaction with calmodulin, HINT2 also modulates mitochondrial calcium signaling, a process intimately linked to cell death decisions. Upstream, HINT2 expression is transcriptionally activated by TP53 and epigenetically silenced by DNA methylation and histone deacetylase (HDAC) activity, frequently observed in hepatocellular carcinoma and colorectal cancer. Downstream targets include BAX, cytochrome c, and calmodulin, thereby integrating apoptosis, calcium, and acetylation networks.
In the Jurkat T lymphoblast model, HINT2 knockout permits detailed dissection of mitochondrial apoptosis signaling within a leukemic background. Since Jurkat cells are derived from acute T cell leukemia, they exhibit abnormal survival signal propagation, and HINT2 loss can help uncover mechanisms of chemoresistance often seen in ALL. The model enables researchers to examine how the absence of HINT2 influences BAX-mediated cytochrome c mobilization and downstream caspase-9 activation, key events that are frequently altered in leukemia. Additionally, the interplay between HINT2-dependent calcium regulation and apoptotic thresholds can be assessed, offering insights into mitochondrial dysfunction in T-cell malignancies.
Researchers can utilize these cells in apoptosis-focused assays such as Annexin V/propidium iodide flow cytometry, caspase activity assays, and subcellular fractionation for cytochrome c release quantification. Cell viability assays (MTT or CCK-8) support drug sensitivity profiling, particularly for chemotherapeutics that target intrinsic apoptosis. Co-immunoprecipitation and western blotting facilitate the study of HINT2 interactions with calmodulin, SIRT3, or GCN5L1, while calcium flux assays allow real-time assessment of mitochondrial calcium dynamics. Broader applications encompass tumor suppressor research, cancer biology, and mitochondrial function studies. For further information, please contact Ascent Research.
